The Pre-Treatment Platelet-to-Lymphocyte Ratio as a Prognostic Factor for Loco-Regional Control in Locally Advanced Rectal Cancer
Chronic inflammatory reactions have been proven to represent relevant mechanisms for the development and progression of cancer in numerous tumor entities. There is evidence that the platelet-to-lymphocyte ratio (PLR) is associated with the prognostic outcome. In rectal cancer, the prognostic role of...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/4/679 |
| _version_ | 1797621543547699200 |
|---|---|
| author | Richard Partl Katarzyna Paal Bettina Stranz Eva Hassler Marton Magyar Thomas Baptist Brunner Tanja Langsenlehner |
| author_facet | Richard Partl Katarzyna Paal Bettina Stranz Eva Hassler Marton Magyar Thomas Baptist Brunner Tanja Langsenlehner |
| author_sort | Richard Partl |
| collection | DOAJ |
| description | Chronic inflammatory reactions have been proven to represent relevant mechanisms for the development and progression of cancer in numerous tumor entities. There is evidence that the platelet-to-lymphocyte ratio (PLR) is associated with the prognostic outcome. In rectal cancer, the prognostic role of this parameter has not yet been conclusively clarified. The aim of this study was to further clarify the prognostic significance of the pre-treatment PLR in patients with locally advanced rectal cancer (LARC). In the present study, 603 patients with LARC, who were treated with neoadjuvant chemoradiotherapy (nCRT) and subsequent surgical resection between 2004 and 2019, were retrospectively evaluated. The influence of clinico-pathological and laboratory factors on locoregional control (LC), metastasis-free survival (MFS) and overall survival (OS) was investigated. In univariate analyses, high PLR was significantly associated with worse LC (<i>p</i> = 0.017) and OS (<i>p</i> = 0.008). In multivariate analyses, the PLR remained an independent parameter for the LC (HR = 1.005, 95% CI: 1.000–1.009, <i>p</i> = 0.050). Pre-treatment lactate dehydrogenase (LDH) (HR: 1.005 95% CI:1.002–1.008; <i>p</i> = 0.001) and carcinoembryonic antigen (CEA) (HR: 1.006, 95% CI:1.003–1.009; <i>p</i> < 0.001) were independent predictors for MFS; additionally, age (HR: 1.052, 95% CI:1.023–1.081; <i>p</i> < 0.001), LDH (HR: 1.003, 95% CI:1.000–1.007; <i>p</i> = 0.029) and CEA (HR: 1.006, 95% CI:1.003–1.009; <i>p</i> < 0.001) independently predicted OS. Pre-treatment PLR before nCRT is an independent prognostic factor for LC in LARC, which could be used to further individualize tumor treatment. |
| first_indexed | 2024-03-11T08:57:29Z |
| format | Article |
| id | doaj.art-f67de57e164b46818af1ecde1161f606 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-11T08:57:29Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-f67de57e164b46818af1ecde1161f6062023-11-16T20:01:23ZengMDPI AGDiagnostics2075-44182023-02-0113467910.3390/diagnostics13040679The Pre-Treatment Platelet-to-Lymphocyte Ratio as a Prognostic Factor for Loco-Regional Control in Locally Advanced Rectal CancerRichard Partl0Katarzyna Paal1Bettina Stranz2Eva Hassler3Marton Magyar4Thomas Baptist Brunner5Tanja Langsenlehner6Department of Therapeutic Radiology and Oncology, Comprehensive Cancer Center, Medical University of Graz, 8036 Graz, AustriaDepartment of Therapeutic Radiology and Oncology, Comprehensive Cancer Center, Medical University of Graz, 8036 Graz, AustriaDepartment of Therapeutic Radiology and Oncology, Comprehensive Cancer Center, Medical University of Graz, 8036 Graz, AustriaDivision of Neuroradiology, Vascular and Interventional Radiology, Comprehensive Cancer Center Graz (CCC), Medical University of Graz, 8036 Graz, AustriaDivision of Neuroradiology, Vascular and Interventional Radiology, Comprehensive Cancer Center Graz (CCC), Medical University of Graz, 8036 Graz, AustriaDepartment of Therapeutic Radiology and Oncology, Comprehensive Cancer Center, Medical University of Graz, 8036 Graz, AustriaDepartment of Therapeutic Radiology and Oncology, Comprehensive Cancer Center, Medical University of Graz, 8036 Graz, AustriaChronic inflammatory reactions have been proven to represent relevant mechanisms for the development and progression of cancer in numerous tumor entities. There is evidence that the platelet-to-lymphocyte ratio (PLR) is associated with the prognostic outcome. In rectal cancer, the prognostic role of this parameter has not yet been conclusively clarified. The aim of this study was to further clarify the prognostic significance of the pre-treatment PLR in patients with locally advanced rectal cancer (LARC). In the present study, 603 patients with LARC, who were treated with neoadjuvant chemoradiotherapy (nCRT) and subsequent surgical resection between 2004 and 2019, were retrospectively evaluated. The influence of clinico-pathological and laboratory factors on locoregional control (LC), metastasis-free survival (MFS) and overall survival (OS) was investigated. In univariate analyses, high PLR was significantly associated with worse LC (<i>p</i> = 0.017) and OS (<i>p</i> = 0.008). In multivariate analyses, the PLR remained an independent parameter for the LC (HR = 1.005, 95% CI: 1.000–1.009, <i>p</i> = 0.050). Pre-treatment lactate dehydrogenase (LDH) (HR: 1.005 95% CI:1.002–1.008; <i>p</i> = 0.001) and carcinoembryonic antigen (CEA) (HR: 1.006, 95% CI:1.003–1.009; <i>p</i> < 0.001) were independent predictors for MFS; additionally, age (HR: 1.052, 95% CI:1.023–1.081; <i>p</i> < 0.001), LDH (HR: 1.003, 95% CI:1.000–1.007; <i>p</i> = 0.029) and CEA (HR: 1.006, 95% CI:1.003–1.009; <i>p</i> < 0.001) independently predicted OS. Pre-treatment PLR before nCRT is an independent prognostic factor for LC in LARC, which could be used to further individualize tumor treatment.https://www.mdpi.com/2075-4418/13/4/679platelet-to-lymphocyte ratio (PLR)inflammationprognosislocally advanced rectal cancer (LARC) |
| spellingShingle | Richard Partl Katarzyna Paal Bettina Stranz Eva Hassler Marton Magyar Thomas Baptist Brunner Tanja Langsenlehner The Pre-Treatment Platelet-to-Lymphocyte Ratio as a Prognostic Factor for Loco-Regional Control in Locally Advanced Rectal Cancer Diagnostics platelet-to-lymphocyte ratio (PLR) inflammation prognosis locally advanced rectal cancer (LARC) |
| title | The Pre-Treatment Platelet-to-Lymphocyte Ratio as a Prognostic Factor for Loco-Regional Control in Locally Advanced Rectal Cancer |
| title_full | The Pre-Treatment Platelet-to-Lymphocyte Ratio as a Prognostic Factor for Loco-Regional Control in Locally Advanced Rectal Cancer |
| title_fullStr | The Pre-Treatment Platelet-to-Lymphocyte Ratio as a Prognostic Factor for Loco-Regional Control in Locally Advanced Rectal Cancer |
| title_full_unstemmed | The Pre-Treatment Platelet-to-Lymphocyte Ratio as a Prognostic Factor for Loco-Regional Control in Locally Advanced Rectal Cancer |
| title_short | The Pre-Treatment Platelet-to-Lymphocyte Ratio as a Prognostic Factor for Loco-Regional Control in Locally Advanced Rectal Cancer |
| title_sort | pre treatment platelet to lymphocyte ratio as a prognostic factor for loco regional control in locally advanced rectal cancer |
| topic | platelet-to-lymphocyte ratio (PLR) inflammation prognosis locally advanced rectal cancer (LARC) |
| url | https://www.mdpi.com/2075-4418/13/4/679 |
| work_keys_str_mv | AT richardpartl thepretreatmentplatelettolymphocyteratioasaprognosticfactorforlocoregionalcontrolinlocallyadvancedrectalcancer AT katarzynapaal thepretreatmentplatelettolymphocyteratioasaprognosticfactorforlocoregionalcontrolinlocallyadvancedrectalcancer AT bettinastranz thepretreatmentplatelettolymphocyteratioasaprognosticfactorforlocoregionalcontrolinlocallyadvancedrectalcancer AT evahassler thepretreatmentplatelettolymphocyteratioasaprognosticfactorforlocoregionalcontrolinlocallyadvancedrectalcancer AT martonmagyar thepretreatmentplatelettolymphocyteratioasaprognosticfactorforlocoregionalcontrolinlocallyadvancedrectalcancer AT thomasbaptistbrunner thepretreatmentplatelettolymphocyteratioasaprognosticfactorforlocoregionalcontrolinlocallyadvancedrectalcancer AT tanjalangsenlehner thepretreatmentplatelettolymphocyteratioasaprognosticfactorforlocoregionalcontrolinlocallyadvancedrectalcancer AT richardpartl pretreatmentplatelettolymphocyteratioasaprognosticfactorforlocoregionalcontrolinlocallyadvancedrectalcancer AT katarzynapaal pretreatmentplatelettolymphocyteratioasaprognosticfactorforlocoregionalcontrolinlocallyadvancedrectalcancer AT bettinastranz pretreatmentplatelettolymphocyteratioasaprognosticfactorforlocoregionalcontrolinlocallyadvancedrectalcancer AT evahassler pretreatmentplatelettolymphocyteratioasaprognosticfactorforlocoregionalcontrolinlocallyadvancedrectalcancer AT martonmagyar pretreatmentplatelettolymphocyteratioasaprognosticfactorforlocoregionalcontrolinlocallyadvancedrectalcancer AT thomasbaptistbrunner pretreatmentplatelettolymphocyteratioasaprognosticfactorforlocoregionalcontrolinlocallyadvancedrectalcancer AT tanjalangsenlehner pretreatmentplatelettolymphocyteratioasaprognosticfactorforlocoregionalcontrolinlocallyadvancedrectalcancer |